Royalty Pharma plc (RPRX) Balance Sheet

The balance sheet has expanded significantly over the past ten quarters, driven primarily by increased debt financing rather than organic equity growth. Total liabilities rose from $6.3B to $10.0B, while equity fluctuated, ending at $9.8B in 2026Q2. This suggests a deliberate strategy of leveraging to fund acquisitions or investments, but the rising D/E ratio indicates a shift toward a more leveraged capital structure, which may increase financial risk if cash flows become volatile.

The company has consistently increased its debt load, with D/E rising from 0.62 to 0.92 over the period. This leverage appears to be a deliberate strategy to fund royalty acquisitions, given the asset-light nature of the business. However, the rising debt-to-assets ratio (from 0.38 to 0.45) suggests a growing reliance on debt, which could strain cash flows if royalty revenues underperform. The absence of near-term maturities is not disclosed, but the trend warrants monitoring for refinancing risk.

The balance sheet is dominated by intangible assets, with goodwill appearing in 2025Q1 and stabilizing around $924M. This reflects the company's business model of acquiring royalty interests, which are not separately disclosed but are likely the primary asset class. The lack of PPE underscores the asset-light nature, but the goodwill balance introduces impairment risk if underlying royalty streams underperform. Investors should monitor the composition of intangibles beyond goodwill, as they are not broken out in the provided data.

Equity has been volatile, influenced by share repurchases and fluctuating net income. Retained earnings have grown from $2.4B to $2.5B, indicating modest profit retention, but the equity jump in 2026Q2 (from $6.9B to $9.8B) suggests a significant non-operating gain or capital raise, which is not evident from the data. The prior cash flow analysis noted opportunistic buybacks, which may have reduced share count and supported equity per share, but the inconsistency in equity levels warrants further investigation into the drivers.

The current ratio has been highly volatile, dropping to 0.97 in 2025Q4, which suggests potential short-term liquidity pressure, but recovering to 1.29 by 2026Q2. Cash balances have fluctuated significantly, with a low of $586M in 2026Q1 and a high of $1.8B in 2024Q2. Given the company's reliance on royalty receipts, which can be lumpy, maintaining an adequate cash buffer is crucial. The 2025Q4 current ratio below 1.0 may indicate a temporary mismatch, but the subsequent recovery suggests it was managed.